Shares of Aratana Therapeutics Inc (NASDAQ:PETX) have earned an average rating of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $8.75.

PETX has been the subject of a number of research reports. HC Wainwright initiated coverage on Aratana Therapeutics in a research note on Friday, November 17th. They issued a “buy” rating and a $10.00 price objective for the company. Jefferies Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research note on Friday, November 3rd. CL King initiated coverage on Aratana Therapeutics in a research note on Wednesday, December 27th. They issued a “neutral” rating for the company. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research note on Thursday, November 9th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Aratana Therapeutics in a research note on Monday, December 18th.

In related news, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the completion of the transaction, the insider now directly owns 529,359 shares of the company’s stock, valued at approximately $3,705,513. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $5.70, for a total value of $5,075,941.20. The disclosure for this sale can be found here. Insiders have sold a total of 1,057,032 shares of company stock valued at $6,186,791 over the last three months. 5.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC grew its stake in Aratana Therapeutics by 22.7% during the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 3,610 shares in the last quarter. ProShare Advisors LLC grew its stake in Aratana Therapeutics by 7.2% during the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 1,709 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Aratana Therapeutics during the 2nd quarter worth $210,000. Parametric Portfolio Associates LLC grew its stake in Aratana Therapeutics by 6.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 1,875 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Aratana Therapeutics by 25.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 6,898 shares in the last quarter. 73.76% of the stock is owned by hedge funds and other institutional investors.

Aratana Therapeutics (NASDAQ PETX) traded down $0.03 during trading hours on Friday, reaching $5.25. The company’s stock had a trading volume of 478,300 shares, compared to its average volume of 354,000. Aratana Therapeutics has a 12 month low of $4.85 and a 12 month high of $8.63. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. The stock has a market capitalization of $223.17, a P/E ratio of -3.62 and a beta of 3.36.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.47 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The company’s revenue was up 1440.0% on a year-over-year basis. equities analysts expect that Aratana Therapeutics will post -1.03 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/aratana-therapeutics-inc-petx-given-average-recommendation-of-hold-by-brokerages.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.